Minhe Pharmaceutical Bureau

Sanming Minhe Pharmaceutical Technology is a contract development and manufacturing organization (CDMO) based in Fujian, China, specializing in the production of pharmaceutical intermediates and specialty chemicals. Acquired by the German biotechnology company Enzymaster in 2021, the company utilizes advanced biocatalysis and enzyme engineering to provide sustainable, "green" manufacturing solutions. Its facilities include a kilogram-level technology development center, pilot-scale production, and robust commercial-scale manufacturing capacity. Sanming Minhe serves as a primary manufacturing hub for Enzymaster's pipeline of compounds, supporting global clients in the pharmaceutical, food, and fine chemical sectors.